Basic Drug Info
Drug Name:Methergine
Manufacturer:Novartis Pharmaceuticals Corporation
Other Info:

There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.

Although there have been no reports of such interactions with methylergonovine alone, potent CYP 3A4 inhibitors should not be coadministered with methylergonovine.

Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).

Less potent CYP 3A4 inhibitors should be administered with caution.

Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.

These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine.      No pharmacokinetic interactions involving other cytochrome P450 isoenzymes are known.      Caution should be exercised when Methergine® (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.

Clinical Trials:

Indications and Usage

For routine management after delivery of the placenta; postpartum atony and hemorrhage; subinvolution.

Under full obstetric supervision, it may be given in the second stage of labor following delivery of the anterior shoulder.
Hypertension; toxemia; pregnancy; and hypersensitivity.
Maternal hypertension --

Hypersensitivity -- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.


This drug should not be administered I.V.

routinely because of the possibility of inducing sudden hypertensive and cerebrovascular accidents.

If I.V.

administration is considered essential as a lifesaving measure, Methergine® (methylergonovine maleate) should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure.

Intra-arterial or periarterial injection should be strictly avoided.

This web-site is for informational purposes only and is not intended as a substitute for advice from your doctor. It should not to be used for self-diagnosis or treatment.